Mechanism of Action: Dipeptidase Inhibitors

Drugs with Mechanism of Action: Dipeptidase Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Merck Co	RECARBRIO	cilastatin sodium; imipenem; relebactam	POWDER;INTRAVENOUS	212819-001	Jul 16, 2019		RX	Yes	Yes
Msd Merck Co	RECARBRIO	cilastatin sodium; imipenem; relebactam	POWDER;INTRAVENOUS	212819-001	Jul 16, 2019		RX	Yes	Yes
Msd Merck Co	RECARBRIO	cilastatin sodium; imipenem; relebactam	POWDER;INTRAVENOUS	212819-001	Jul 16, 2019		RX	Yes	Yes
Msd Merck Co	RECARBRIO	cilastatin sodium; imipenem; relebactam	POWDER;INTRAVENOUS	212819-001	Jul 16, 2019		RX	Yes	Yes	8,487,093		Y	Y
Merck	PRIMAXIN	cilastatin sodium; imipenem	POWDER;INTRAVENOUS	050587-001	Nov 26, 1985		DISCN	Yes	No

Dipeptidase Inhibitors Market Dynamics and Patent Landscape

Last updated: August 1, 2026

Dipeptidase inhibitors are led commercially by dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes, including sitagliptin, linagliptin, saxagliptin, alogliptin, vildagliptin, teneligliptin, gemigliptin and omarigliptin. The class generated substantial revenue before U.S. composition-of-matter patents expired, but generic entry has compressed prices in major markets. Patent value has shifted from core molecules to salts, crystalline forms, formulations, combination products, manufacturing processes and method-of-use claims.

Cilastatin is a separate dipeptidase inhibitor used with imipenem. Its commercial exposure is smaller and its patent barriers are less significant than those for DPP-4 medicines. No approved DPP-4 inhibitor is a biologic, so biosimilar substitution is not the principal competitive threat. The relevant risk is generic small-molecule entry under abbreviated new drug application pathways.

What drugs are classified as dipeptidase inhibitors?

Dipeptidase inhibition covers multiple enzyme targets. The commercially important group is DPP-4 inhibition, which increases endogenous incretin activity and lowers blood glucose in type 2 diabetes. Renal dehydropeptidase-I inhibition is the mechanism associated with cilastatin.

Major DPP-4 inhibitors

Drug	Brand	Principal company	First major approval	Primary market position
Sitagliptin	Januvia, Janumet	Merck	2006	First-in-class U.S. DPP-4 inhibitor; historically the largest product
Saxagliptin	Onglyza, Kombiglyze XR	AstraZeneca	2009	Chronic oral diabetes product; combination exposure
Linagliptin	Tradjenta, Jentadueto	Boehringer Ingelheim/Eli Lilly	2011	Renal-dose convenience and once-daily dosing
Alogliptin	Nesina, Kazano, Oseni	Takeda	2013	Smaller U.S. commercial position
Vildagliptin	Galvus, Eucreas	Novartis	2007 in Europe	Broad international use; not approved in the United States
Teneligliptin	Tenelia	Mitsubishi Tanabe and regional partners	2012 in Japan	Japan and selected Asian markets
Gemigliptin	Zemiglo	LG Chem	2012 in South Korea	South Korea and selected international markets
Omarigliptin	Marizev	MSD/Kyowa Kirin	2015 in Japan	Once-weekly product; Japan-focused
Trelagliptin	Wedica	Takeda	2015 in Japan	Once-weekly product; Japan-focused

The class competes with metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, dual incretin agonists and sodium-glucose cotransporter-2 inhibitors. DPP-4 inhibitors retain demand because they are oral, generally weight-neutral and associated with a comparatively low hypoglycemia risk when used without insulin or insulin secretagogues.

Cilastatin and other non-DPP-4 products

Cilastatin inhibits renal dehydropeptidase-I and is administered with imipenem to prevent renal metabolism of imipenem. The combination is marketed as imipenem/cilastatin, including Primaxin and generic equivalents. Relebactam, marketed with imipenem/cilastatin as Recarbrio, is a beta-lactamase inhibitor and does not make the product a DPP-4 medicine.

How does the DPP-4 inhibitor market compare with competing diabetes drugs?

DPP-4 inhibitors occupy an established but slower-growth segment of diabetes treatment. GLP-1 receptor agonists and SGLT2 inhibitors have taken share in patients with obesity, cardiovascular disease, heart failure or chronic kidney disease. Their clinical-outcome data and weight effects have supported premium pricing.

Segment	Commercial advantage	Principal weakness	Patent and competition profile
DPP-4 inhibitors	Oral dosing, tolerability, weight neutrality	Limited weight loss and outcome differentiation	Generic erosion is advanced for older molecules
GLP-1 receptor agonists	Weight loss and cardiometabolic demand	Injectable delivery for many products and higher cost	Formulation, device and manufacturing patents remain important
SGLT2 inhibitors	Cardiovascular and renal outcome positioning	Genitourinary adverse effects and class-specific contraindications	Major products have recently reached or are approaching generic risk
Metformin	Low cost and long clinical history	Gastrointestinal tolerability and limited use in some patients	Minimal patent protection
Sulfonylureas	Low acquisition cost and efficacy	Hypoglycemia and weight gain	Generic market

Sitagliptin and linagliptin have had the strongest U.S. commercial profiles. Saxagliptin is exposed to combination-product and cardiovascular-label considerations. Alogliptin has a smaller revenue base. Vildagliptin, teneligliptin and gemigliptin are more dependent on non-U.S. markets, where local patent expiry and regulatory standards determine generic timing.

What patents protect DPP-4 inhibitors?

Core composition patents created the principal barriers to entry. Secondary patents extend protection around salt forms, solid-state forms, combinations, dosage regimens and manufacturing methods.

Product	Representative patent estate	U.S. patent position and market effect
Januvia, sitagliptin	U.S. Patent No. 6,699,871; related phosphate-salt and formulation patents	Core protection expired in 2022; Merck settlement agreements delayed or staged generic entry, with U.S. generic availability beginning in 2026 under announced arrangements
Janumet, sitagliptin/metformin	Sitagliptin composition and combination patents	Combination claims and listed patents created separate ANDA litigation exposure; generic competition follows the sitagliptin settlement framework
Tradjenta, linagliptin	U.S. Patent No. 7,407,955 and related patents	Core protection has been treated as extending into the mid-2020s; formulation and combination claims remain relevant
Onglyza, saxagliptin	U.S. Patent No. 6,525,027 and related product patents	Core patents expired earlier than the principal sitagliptin estate; generic and authorized-generic competition has increased
Nesina, alogliptin	U.S. Patent No. 6,395,767 and related patents	Core protection expired in the 2020s; U.S. product exposure is now primarily commercial rather than exclusivity-driven
Galvus, vildagliptin	International composition, formulation and process patents	No U.S. Orange Book position because the product lacks U.S. approval; protection varies materially by country
Tenelia, teneligliptin	National composition, crystalline-form and process patents	Japan and Asian-market patents, rather than U.S. patents, drive value
Zemiglo, gemigliptin	Korean and international composition and formulation patents	Regional patent strength and licensing arrangements determine market access
Marizev, omarigliptin	Japanese composition and formulation patents	Japan-specific commercial and patent exposure
Imipenem/cilastatin	Older imipenem and cilastatin patents; later formulation and process rights	Core small-molecule protection is largely historical; current competition is based on regulatory approval, supply and hospital contracting

Patent numbers in the table identify representative core rights rather than every Orange Book-listed patent. Patent families differ by jurisdiction, continuation practice and terminal disclaimers. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, remains the controlling source for U.S. listed patents and pediatric exclusivity data. (U.S. Food and Drug Administration [FDA], 2025a)

What formulations are protected by DPP-4 inhibitor patents?

Secondary protection commonly covers:

• Phosphate, hydrochloride and other pharmaceutically acceptable salts.
• Crystalline or polymorphic forms.
• Immediate-release tablets and fixed-dose combinations.
• Extended-release metformin combinations.
• Specific impurity limits and particle-size distributions.
• Manufacturing processes for chiral intermediates.
• Dosage regimens, including renal impairment dosing and combination therapy.

The commercial value of formulation patents is usually lower than the value of a valid composition patent because ANDA applicants can design around some formulation claims. Their importance rises when the branded product is a fixed-dose combination or when the active ingredient is difficult to crystallize or purify at commercial scale.

When do DPP-4 inhibitors lose U.S. exclusivity?

The main U.S. exclusivity transitions are molecule-specific. FDA approval exclusivity and patent exclusivity are separate. A drug can lose regulatory exclusivity while remaining protected by listed patents, or retain patents after regulatory exclusivity ends.

Product	U.S. approval exclusivity	Core patent transition	Current strategic issue
Januvia	New chemical entity exclusivity expired in 2011	Core patent expired in 2022; settlement-based generic timing extends practical protection	Large installed base and major combination-product exposure
Onglyza	New chemical entity exclusivity expired in 2014	Core patent protection expired earlier than Januvia	Price erosion and generic substitution
Tradjenta	New chemical entity exclusivity expired in 2016	Core estate extends into the mid-2020s for key U.S. rights	Later-entry generic risk and combination products
Nesina	New chemical entity exclusivity expired in 2018	Core estate moved into generic-risk period in the 2020s	Smaller revenue base
Vildagliptin	Country-specific	European and Asian expiries vary	No U.S. launch pathway
Teneligliptin, gemigliptin, omarigliptin	Country-specific	National patent and regulatory expiries vary	Regional rather than global exposure

Sitagliptin remains the most consequential U.S. patent event because Januvia and Janumet generated substantial branded revenue. Merck disclosed that authorized and settlement-based generic competition would begin in the United States in 2026, subject to the relevant agreements and product approvals. (Merck & Co., 2024)

Which companies are challenging DPP-4 inhibitor patents?

Generic manufacturers have challenged DPP-4 products through Paragraph IV certifications under the Hatch-Waxman Act. The most active participants in this market include Teva, Sandoz, Zydus, Dr. Reddy’s, Sun Pharma, Lupin, Torrent, Aurobindo and Viatris, depending on the molecule and jurisdiction.

Paragraph IV exposure

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or not infringed. The filing can trigger patent litigation and a 30-month stay of FDA approval for the ANDA, subject to statutory exceptions.

The practical pattern has been:

1. Early ANDA filings target core composition or salt patents.
2. Sponsors litigate or settle before final trial in many cases.
3. Settlements establish licensed generic dates, authorized-generic terms or supply arrangements.
4. Generic entry then expands quickly once the first approved product launches.

Sitagliptin illustrates the value of settlement analysis. A generic applicant may obtain an approval date that is materially earlier than the nominal expiration of a secondary patent if the settlement grants a license or permits launch under specified conditions. The relevant commercial date is therefore the earliest permitted launch date, not simply the latest Orange Book expiry date.

What is the Orange Book status of DPP-4 inhibitors?

U.S.-approved DPP-4 inhibitors and their fixed-dose combinations have had Orange Book-listed patents. The principal products include:

• Januvia, sitagliptin phosphate.
• Janumet and Janumet XR, sitagliptin/metformin.
• Onglyza and Kombiglyze XR, saxagliptin.
• Tradjenta and Jentadueto, linagliptin.
• Nesina, Kazano and Oseni, alogliptin combinations.

Orange Book analysis should separate three questions:

Question	Relevance
Is the active ingredient approved?	Determines whether an ANDA can reference the product
Are patents listed?	Determines certification and litigation exposure
Is pediatric exclusivity attached?	Can add six months to applicable patent protection

Orange Book listings do not establish that a patent will survive invalidity or infringement review. They identify the patents that an ANDA applicant must address. FDA’s patent listing database and product-specific labels should be reviewed together because the listing may include composition, formulation and method-of-use claims. (FDA, 2025a; FDA, 2025b)

What patent litigation and settlements affect the class?

The class has generated the most litigation around sitagliptin, its phosphate salt and sitagliptin/metformin combinations. The disputes have involved:

• Validity of core compound claims.
• Scope of phosphate-salt claims.
• Infringement by generic sitagliptin products.
• Fixed-dose combination patents.
• Pediatric exclusivity and permitted generic launch dates.

Saxagliptin and alogliptin have also faced generic-entry activity, but their lower U.S. revenue bases reduce the settlement value relative to sitagliptin. Linagliptin has had a later and more valuable U.S. patent position, making its remaining Orange Book estate more commercially relevant.

Settlement terms can include confidential commercial provisions. Publicly disclosed terms may identify entry dates without fully disclosing supply, royalty or authorized-generic arrangements. Investors and licensees should treat the earliest settlement-permitted launch date as the key date for revenue modeling.

How strong is the patent estate for each DPP-4 inhibitor?

Patent strength is strongest when the sponsor has multiple independent barriers that cannot be readily designed around.

Patent attribute	Strength assessment
Valid composition-of-matter claim	Very high
Valid salt or polymorph claim with limited alternatives	High
Fixed-dose combination claim	Moderate to high
Formulation claim with simple tablet design	Moderate
Manufacturing-process claim	Variable; depends on proof of process use
Method-of-use claim	Variable; depends on labeling and induced-infringement evidence
Broad treatment claim after core expiry	Usually lower against an ANDA

Sitagliptin had a high-value core estate because of the size of its patient base and the importance of Januvia and Janumet. Linagliptin has retained meaningful value from later U.S. patent coverage and renal-dose positioning. Older saxagliptin and alogliptin assets are weaker as standalone exclusivity platforms because generic alternatives have had more time to enter.

What generic entry risks exist for DPP-4 inhibitors?

Generic entry risk is determined by patent expiry, Paragraph IV activity, settlement dates, regulatory approval and manufacturing capacity.

Generic launch scenarios

Scenario	Likely market effect
First generic launch with 180-day exclusivity	Rapid discounting, followed by accelerated price erosion
Authorized generic launches with a Paragraph IV product	Lower first-wave prices and reduced value of exclusivity
Multiple ANDAs launch simultaneously	Steep volume migration to generic products
Fixed-dose combination remains protected	Partial erosion; monotherapy loses share first
Generic active ingredient launches but branded combination remains protected	Prescribers may substitute separate components
No ANDA approval despite patent expiry	Delayed commercial erosion caused by manufacturing or regulatory constraints

DPP-4 products are relatively straightforward oral solid-dose products. Manufacturing complexity is lower than for sterile injectables or biologics. The principal supply barriers are API quality, impurity control, chiral synthesis, crystallization and regulatory consistency. These barriers can slow entry but rarely provide durable protection after multiple suppliers qualify.

Is there biosimilar risk for DPP-4 inhibitors?

There is no conventional biosimilar risk for DPP-4 inhibitors because they are chemically synthesized small molecules. The competitive pathway is an ANDA with pharmaceutical equivalence and bioequivalence requirements.

Cilastatin and imipenem/cilastatin are also small molecules. Biosimilar regulation under the Public Health Service Act does not apply. The relevant risks are generic substitution, hospital formulary contracting, procurement tenders and shortages.

How does the DPP-4 patent landscape vary geographically?

U.S. patent expiry is only one part of the global analysis. Europe, Japan, South Korea, India and China have separate patent terms, supplementary protection certificate rules, regulatory exclusivity systems and litigation procedures.

• European protection may include supplementary protection certificates, but their value depends on the original patent, authorization timing and country.
• Japan is commercially important for teneligliptin and omarigliptin, where domestic reimbursement and patent timing influence uptake.
• South Korea is central to gemigliptin and has a strong domestic generic industry.
• India has a large generic manufacturing base and can affect global API and finished-dose pricing.
• China has growing domestic DPP-4 competition and increasingly active centralized procurement, which can reduce prices even before global patent expiry.

Vildagliptin illustrates geographic divergence. It has been widely commercialized outside the United States, while the U.S. market has no branded product or corresponding Orange Book estate.

What licensing deals affect DPP-4 inhibitor commercialization?

DPP-4 commercialization has relied on regional licensing, co-development and co-promotion arrangements. Notable structures include:

• Boehringer Ingelheim and Eli Lilly’s alliance covering linagliptin and diabetes products.
• Merck’s regional partnerships for sitagliptin commercialization.
• Kyowa Kirin’s Japanese commercialization role for omarigliptin.
• Regional licensing and commercialization arrangements for gemigliptin and teneligliptin.

License value depends on territorial patent life, reimbursement access, local clinical requirements and the ability to combine the product with metformin or other glucose-lowering agents. A license with short remaining patent life is more valuable when it includes manufacturing rights, an established sales channel or an approved fixed-dose combination.

What is the revenue exposure from DPP-4 patent expiry?

Revenue exposure is concentrated in a few global brands. Sitagliptin has historically represented the largest single opportunity for generic substitution. Linagliptin has retained later-life value in the U.S. and selected international markets. Saxagliptin and alogliptin are more mature products with lower branded growth prospects.

A practical exposure model should use:

• Branded net sales by product and geography.
• The earliest settlement-permitted generic date.
• Expected first-generic discount.
• Number of approved ANDAs.
• Authorized-generic participation.
• Fixed-dose combination substitution.
• Reimbursement and tender dynamics.
• Manufacturer API capacity.

The class remains commercially relevant after patent expiry because DPP-4 inhibitors are used chronically and have broad prescribing familiarity. Patent expiry changes price and margin structure rather than eliminating demand.

Key Takeaways

• DPP-4 inhibitors are the main commercial segment within dipeptidase inhibitors.
• Sitagliptin has the largest historical U.S. patent and revenue exposure.
• Linagliptin has one of the more valuable later-life U.S. patent positions.
• Saxagliptin and alogliptin are further along the generic-erosion curve.
• Vildagliptin, teneligliptin, gemigliptin and omarigliptin require country-specific patent analysis.
• Formulation, salt, polymorph, combination and manufacturing patents provide secondary protection but are less durable than composition patents.
• Paragraph IV litigation and settlement agreements can move generic launch dates ahead of nominal patent expiries.
• Biosimilars are not the relevant threat; ANDA-based generic substitution is.
• Manufacturing complexity is moderate and unlikely to create a durable post-expiry barrier.
• Competitive pressure from GLP-1 receptor agonists and SGLT2 inhibitors limits long-term pricing power even where patent protection remains.

FAQs

Does sitagliptin have generic competition in the United States?

Generic sitagliptin products have been approved or authorized under settlement-related arrangements, with commercial entry scheduled under disclosed agreements beginning in 2026.

Which DPP-4 inhibitor has the longest remaining patent protection?

Linagliptin has generally had the later U.S. core patent position among the major U.S.-approved DPP-4 inhibitors, although the commercial date depends on Orange Book listings, pediatric exclusivity and settlement terms.

Is vildagliptin protected by U.S. patents?

Vildagliptin has international patent protection but is not FDA-approved in the United States. It therefore has no U.S. Orange Book product listing comparable to Januvia, Tradjenta or Onglyza.

Can a generic company avoid DPP-4 method-of-use patents?

An ANDA applicant can use a Section viii statement to carve out a patented method of use when the remaining label omits that indication. The viability of the strategy depends on the exact patent claims and proposed labeling.

Are DPP-4 inhibitor combination products harder to launch generically?

They can be. Fixed-dose combinations may have separate formulation, dosage and method-of-use patents, and a generic company may need to address both the active-ingredient estate and the combination-product estate.

References

1. Merck & Co. (2024). Annual report 2024. https://www.merck.com
2. U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
3. U.S. Food and Drug Administration. (2025b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of abbreviated new drug applications. https://www.fda.gov
5. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension. https://www.uspto.gov
6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
7. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/